At 35k a year, the average CCR5 cancer patient in

At 35k a year, the average CCR5 cancer patient in their 60s and 70s and 80s may have the option to skip or do lower dose chemo, radio, or surgery, and get 11-12 years of leronlimab at the same cost of one 400k CART treatment. With that extra time, they get to live close to a full life until they pass on from other causes maybe. This would be similar to how sometimes we do not aggressively treating low grade prostate cancer in older men currently since they often ride out the cancer in their last year's of life and have higher quality of life without side effects

All the above is just my opinion.